Shots:
- This agreement will expand Mustang’s pipeline of ex vivo lentiviral gene therapies for the treatment of SCID
- Lentiviral gene therapy is currently being evaluated in a P-I/II clinical trial in the EU and has also received an ODD from the EMA for the RAG1-SCID program. The company plans to advance its therapy for RAG1-SCID to make it available for the patients
- Mustang’s lead products, MB-107, and MB-207 are currently being evaluated for the treatment of XSCID & is expected to enroll its 1st patient in a trial of MB-107 in Q1’22
Click here to read the full press release/ article | Ref: Globe Newswire | Image: Mustang Bio
The post Mustang Bio Signs an Exclusive WW License Agreement with Leiden University Medical Centre for Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency first appeared on PharmaShots.
